3D Tissue Models Summit

Memo

The 3D Tissue Models Summit will bring together 120+ industry stakeholders across the regulatory, pharma, biotech and academic landscapes to discuss the latest insight into established validation techniques to increase reproducibility and improve the preclinical effectiveness of drug candidates. Join us and discover:20+ latest case studies showcasing the advantages of high throughput screening techniques across the 3D model continuum to drive drug discovery progress.FDA guidance into the regulatory landscape to define a common language of key terms across the industry for end users.NIH and IQ Consortia discussing the latest developments to incorporate platform-specific standardization and reproducibility metrics for organoids and tissue chip technology.Model developers and academic experts revealing how to overcome translational challenges to define disease-relevant endpoints across a variety of model types. Take advantage of this unrivalled learning and networking opportunity packed with content and dedicated interactive formats to ensure you leave equipped with the connections and takeaways to enhance the predictive success of your preclinical 3D models.URLs:Tickets: https://go.evvnt.com/431274-1?pid=5569Brochure: https://go.evvnt.com/431274-3?pid=5569PriceStandard Conference Price: USD 2666.0Early Bird Conference Only Price: USD 2099.0Standard Conference + 3 Workshops Price: USD 3897.0Artists / Speakers: Suzanne Fitzpatrick,  Senior Advisor for Toxicology Center for Food Safety and Applied Nutrition,  U.S Food and Drug Administration, Steve Ferguson,  Principal Scientist, National Institute of Environmental Health Sciences (NIEHS), Will Proctor, Associate Director Investigative Toxicology,  Genentech, Janine McCarthy, Research Specialist, Physician's Committee for Responsible Medicine, Lans Taylor; Director - Drug Discovery Institute & Professor - Allegheny Foundation; University of Pittsburgh, Wen Kang, Principal Scientist, Merck, Murat Cirit; Director, Translational Center & Tissue Chip Technologies; MIT, Matthias Von Herrath;  Vice President;  Novo Nordisk, Yu Chi Chen; Scientist; National Institute of Health Sciences (NIH), William Murphy; Harvey D. Spangler Professor and Founding Director, Forward BIO Institute; University of Wisconsin, Anshul Gupta; Principal Scientist - Pharmacokinetics & Drug Metabolism; Amgen, Bhushan Mahadik; Assistant Director of Engineering & Complex Tissues; University of Maryland, Fabian Zanella; Director of R&D; Stemonix, Matthew Lech; Senior Research Scientist; Pfizer, John Wikswo; Professor and Founding Director; Vanderbilt Institute for Integrative Biosystems Research and Education (VIIBRE), Richard Visconti; Principal Scientist; Celgene, Joe Charest; Program Manager; Draper, Szczepan Baran; Head of Emerging Technologies; Novartis, Caghan Kizil; Group Leader; Center for Neurodegenerative Diseases, Helmholtz Association, Misti Ushio; CEO; Tara Biosystems, Nathan Hotaling; Lead Data Scientist; National Center for Advancing Translational Sciences (NCATS), Matthew Wagoner; Associate Director - Mechanistic & Investigative Toxicology; Takeda, Sandra Engle; Director - Translational Cell Sciences, Stem Cells & Genomic Engineering; Biogen, Regis Doyonnas; Associate Research Fellow & Senior Principal Scientist; Pfizer, Girija Goyal; Research Scientist; Wyss Institute for Biologically Inspired Engineering, Janice Moser; Director of Immunological Research; Sanofi Pasteur, Prathap Kumar S. Mahalingaiah; Senior Scientist, Investigative Toxicology & Pathology; AbbVieTime:  8:00 am to 5:00 pmVenue detailsHilton Boston Back Bay40 Dalton Street, Boston 02115, United States